Search

Drug Profiles Catalysts Company Profiles Impact Events Target
Indication Trials KOL Insight Special Reports All

Drug Impact Events

Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
4/28/15 Cerulean Pharma (CERU) CRLX101 for Renal Cell Cancer (RCC) Subscribers Only Subscribers Only Subscribers Only
4/28/15 Sanofi (SNY) GZ402671 for Fabry's Disease Subscribers Only Subscribers Only Subscribers Only
4/27/15 Merck (MRK) Januvia for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
4/27/15 Merrimack Pharmaceuticals (MACK) MM-398 for Pancreatic Cancer Subscribers Only Subscribers Only Subscribers Only
4/27/15 Galapagos (GLPG) Filgotinib for Rheumatoid Arthritis (RA) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

Expected
Date Range
Lead
Company
Drug Expected
Catalyst
04/28/15 Subscribers Only Subscribers Only Regulatory - PDUFA/Approval Decision (US)
04/28/15 Subscribers Only Subscribers Only Regulatory - PDUFA/Approval Decision (US)
04/28/15 Subscribers Only Subscribers Only Trial Data - Other
04/28/15 Subscribers Only Subscribers Only Trial Data - Other
04/28/15 Subscribers Only Subscribers Only Trial Data - Updated Results